| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
Top Articles - Pride of Trading
If fear is a powerful emotion, I believe that combining that with pride is an even more dangerous emotional condition to avo According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product id while trading. This is the fear of humiliation, or in other words, pride. For many it is very difficult to admit being wr ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ong. In the market, that tendency to never give up and to tough it out works against us. The market does not care about your lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. perseverance and courage. Those qualities are not recognized as strengths in the market. In fact, they are actually weaknes here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe es in trading. Have you ever entered a trade where it goes your way at the start, but reverses at some point? You just let d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro it ride for a few days, because it was going so well before. You might even suspend your stop loss because, after all, the s ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc tock went the right way at first, and you just cannot be wrong about this. The stock bounces back up a bit, and you are feel easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ng vindicated. Then comes the day that the stock drops quickly, and you freeze up. You did not put in your stop order; you d nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically o not know what to do. But your overall concern is what others will think. You are embarrassed; you do not want to admit def and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ eat. Eventually you either sell at a much lower level than your original stop was at or you are still holding onto that stoc ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ‘knowing’ that it will come back at some point. The fear of humiliation allows us to lie to ourselves. We make excuses for ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ourselves. We tell our friends that it was the market’s fault that that trade went bad. But the market will never be what y dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ou want it to be, just because you want it to be. The market will act as it wants and you must accept that and deal with it. cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin The market is not alive, it does not experience emotion and, most importantly, it is under no obligation to be fair. The a tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen swer is to channel our emotions in a positive direction. Keep trying to learn more and become a better trader. Do not get up t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel set over small losses when you hold to your stops. View stops as a cost of doing business. Learn from your mistakes, but do ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust not continually look back on them and beat yourself up about them, but view them as bumps in the road on the way to becoming y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products a successful trader. After any experience like this, move forward with the resolve to not make the same mistakes again. Eve . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ry great trader starts out with mistakes. If you can minimize the financial pain from these mistakes, and learn from them, y elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ou are on your way to becoming that great trader. Learn the warning signs of pride in your trading, and work to correct them tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Practical Tips for Brochure Design A Career In Medical Transcription: Is It For You? Discover How to Find the Best Online Jobs
|